Trulicity Side Effects
Trulicity (dulaglutide) most commonly causes gastrointestinal side effects including nausea (12-21%), diarrhea (9-13%), vomiting (6-13%), abdominal pain (7-9%), and decreased appetite (5-9%), with most being mild to moderate in severity. 1
Common Gastrointestinal Effects
The most frequent adverse reactions are dose-dependent and include:
- Nausea: 12.4% at 0.75 mg, 21.1% at 1.5 mg 1
- Diarrhea: 8.9% at 0.75 mg, 12.6% at 1.5 mg 1
- Vomiting: 6.0% at 0.75 mg, 12.7% at 1.5 mg 1
- Abdominal pain: 6.5% at 0.75 mg, 9.4% at 1.5 mg 1
- Decreased appetite: 4.9% at 0.75 mg, 8.6% at 1.5 mg 1
Additional GI effects include constipation (3.7-3.9%), flatulence (1.4-3.4%), gastroesophageal reflux (1.7-2.0%), and dyspepsia (4.1-5.8%) 1. Approximately 3.5% of patients discontinue treatment due to GI adverse reactions 1. These effects can be mitigated through slow dose titration, reducing meal size, avoiding high-fat or spicy foods, and mindful eating practices 2, 3.
Serious Adverse Effects (Rare but Critical)
Pancreatitis
Acute pancreatitis occurs in approximately 1.4 cases per 1000 patient-years 1. Discontinue Trulicity immediately if pancreatitis is suspected—look for persistent severe abdominal pain radiating to the back, with or without vomiting 1. Do not restart if pancreatitis is confirmed. Avoid initiating in patients at high risk for pancreatitis 2.
Thyroid C-Cell Tumors
Dulaglutide causes thyroid C-cell tumors in rodents; human relevance is unknown 1. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1. Counsel patients about neck mass, dysphagia, dyspnea, or persistent hoarseness 1.
Gallbladder Disease
Evaluate for cholelithiasis or cholecystitis if patients develop upper abdominal pain, fever, jaundice, or clay-colored stools 1. Avoid use in at-risk individuals 2.
Acute Kidney Injury
GI symptoms (diarrhea, nausea, vomiting) may cause dehydration leading to acute kidney injury, particularly in patients with pre-existing kidney problems 1.
Diabetic Retinopathy Complications
Close monitoring required in high-risk patients—specifically those with diabetes duration ≥10 years or older age 2.
Hypoglycemia Risk
Hypoglycemia risk is minimal with Trulicity monotherapy but increases when combined with insulin secretagogues (sulfonylureas) or insulin 2. In placebo-controlled trials, hypoglycemia with glucose <54 mg/dL occurred in only 0.3% of patients on monotherapy 1.
Other Notable Adverse Effects
- Fatigue: 4.2-5.6% 1
- Allergic reactions: Rare but serious—discontinue if anaphylaxis, angioedema, severe rash, or breathing problems occur 1
- Pulmonary aspiration risk: During surgery or procedures requiring anesthesia due to delayed gastric emptying; inform all healthcare providers before scheduled procedures 1
- Ileus: Risk level not well established; provide guidance on discontinuation prior to surgical procedures 2
- Euglycemic diabetic ketoacidosis: Rare but documented case reports exist 4
Contraindications and Precautions
Absolute contraindications 1:
- Personal or family history of MTC or MEN 2
- Serious hypersensitivity to dulaglutide
Avoid or use with extreme caution in:
- Severe gastroparesis or severe gastrointestinal disease 1
- History of pancreatitis 2
- Gallbladder disease risk 2
Clinical Context
Real-world studies confirm the safety profile: in Korean patients (n=3,022), 60.81% of adverse events were considered related to dulaglutide, with most being mild in severity 5. Chinese real-world data (n=3,291) showed nausea (5.9%), diarrhea (5.6%), and decreased appetite (5.4%) as most common, with 6.4% discontinuation due to adverse events 6. The medication is generally well tolerated when initiated at low doses with gradual titration 3, 5, 6.